Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
183
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 48 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 19 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| — | Bevacizumab | EMA EU | cancer not stated in this record | Treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian… | centralisedEMEA/H/C/005611 | withdrawnsince Jun 21, 2021 | ema |
| — | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AZACITIDINE FOR INJECTION (DIN 02571102) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug… | DIN02571102 | approved | health-canada-dpd |
| — | Carboplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CARBOPLATIN INJECTION BP (DIN 02570963) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug… | DIN02570963 | approved | health-canada-dpd |
| — | Enzalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-ENZALUTAMIDE (DIN 02570831) under ATC L02BB04 ENZALUTAMIDE. Indications are not published in the Drug Product… | DIN02570831 | approved | health-canada-dpd |
| — | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as EUGIA-ABIRATERONE (DIN 02570645) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02570645 | approved | health-canada-dpd |
| — | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as EUGIA-ABIRATERONE (DIN 02570637) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02570637 | approved | health-canada-dpd |
| — | Camizestrant | Health Canada CA | cancer not stated in this record | Marketed in Canada as ETCAMAH (DIN 02570572) under ATC L02BA05 CAMIZESTRANT. Indications are not published in the Drug Product Database —… | DIN02570572 | approved | health-canada-dpd |
| — | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYCLOPHOSPHAMIDE FOR INJECTION USP (DIN 02570475) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published… | DIN02570475 | approved | health-canada-dpd |
| — | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYCLOPHOSPHAMIDE FOR INJECTION USP (DIN 02570467) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published… | DIN02570467 | approved | health-canada-dpd |
| — | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYCLOPHOSPHAMIDE FOR INJECTION USP (DIN 02570459) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published… | DIN02570459 | approved | health-canada-dpd |
| — | Palbociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-PALBOCICLIB (DIN 02570157) under ATC L01EF01 PALBOCICLIB. Indications are not published in the Drug Product… | DIN02570157 | approved | health-canada-dpd |
| — | Palbociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-PALBOCICLIB (DIN 02570149) under ATC L01EF01 PALBOCICLIB. Indications are not published in the Drug Product… | DIN02570149 | approved | health-canada-dpd |
| — | Palbociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-PALBOCICLIB (DIN 02570130) under ATC L01EF01 PALBOCICLIB. Indications are not published in the Drug Product… | DIN02570130 | approved | health-canada-dpd |
| — | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as RIVA-ABIRATERONE (DIN 02569981) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02569981 | approved | health-canada-dpd |
| — | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as RIVA-ABIRATERONE (DIN 02569973) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02569973 | approved | health-canada-dpd |
| — | Tovorafenib | Health Canada CA | cancer not stated in this record | Marketed in Canada as OJEMDA (DIN 02569876) under ATC L01EC04 TOVORAFENIB. Indications are not published in the Drug Product Database — see… | DIN02569876 | approved | health-canada-dpd |
| — | Tovorafenib | Health Canada CA | cancer not stated in this record | Marketed in Canada as OJEMDA (DIN 02569817) under ATC L01EC04 TOVORAFENIB. Indications are not published in the Drug Product Database — see… | DIN02569817 | approved | health-canada-dpd |
| — | Leniolisib | Health Canada CA | cancer not stated in this record | Marketed in Canada as JOENJA (DIN 02569809) under ATC L03AX22 LENIOLISIB. Indications are not published in the Drug Product Database — see… | DIN02569809 | approved | health-canada-dpd |
| — | Selumetinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as KOSELUGO GRANULES (DIN 02569744) under ATC L01EE04 SELUMETINIB. Indications are not published in the Drug Product… | DIN02569744 | approved | health-canada-dpd |
| — | Selumetinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as KOSELUGO GRANULES (DIN 02569736) under ATC L01EE04 SELUMETINIB. Indications are not published in the Drug Product… | DIN02569736 | approved | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as MAR-TEMOZOLOMIDE (DIN 02569345) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02569345 | approved | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as MAR-TEMOZOLOMIDE (DIN 02569337) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02569337 | approved | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as MAR-TEMOZOLOMIDE (DIN 02569329) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02569329 | approved | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as MAR-TEMOZOLOMIDE (DIN 02569310) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02569310 | approved | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as MAR-TEMOZOLOMIDE (DIN 02569302) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02569302 | approved | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as MAR-TEMOZOLOMIDE (DIN 02569299) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02569299 | approved | health-canada-dpd |
| — | Nintedanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as GLN-NINTEDANIB (DIN 02569248) under ATC L01EX09 NINTEDANIB. Indications are not published in the Drug Product… | DIN02569248 | approved | health-canada-dpd |
| — | Nintedanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as GLN-NINTEDANIB (DIN 02569221) under ATC L01EX09 NINTEDANIB. Indications are not published in the Drug Product… | DIN02569221 | approved | health-canada-dpd |
| — | Enzalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PRO-ENZALUTAMIDE (DIN 02569124) under ATC L02BB04 ENZALUTAMIDE. Indications are not published in the Drug Product… | DIN02569124 | approved | health-canada-dpd |
| — | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as BEVQOLVA (DIN 02567865) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database —… | DIN02567865 | approved | health-canada-dpd |
| — | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as BEVQOLVA (DIN 02567830) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database —… | DIN02567830 | approved | health-canada-dpd |
| — | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CAMCEVI (DIN 02567148) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database —… | DIN02567148 | approved | health-canada-dpd |
| — | Thiotepa | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEPADINA (DIN 02567059) under ATC L01AC01 THIOTEPA. Indications are not published in the Drug Product Database — see… | DIN02567059 | approved | health-canada-dpd |
| — | Nivolumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as OPDIVO SC (DIN 02566931) under ATC L01FF01 NIVOLUMAB. Indications are not published in the Drug Product Database —… | DIN02566931 | approved | health-canada-dpd |
| — | Dacarbazine | Health Canada CA | cancer not stated in this record | Marketed in Canada as DACARBAZINE FOR INJECTION (DIN 02566710) under ATC L01AX04 DACARBAZINE. Indications are not published in the Drug… | DIN02566710 | approved | health-canada-dpd |
| — | Dacarbazine | Health Canada CA | cancer not stated in this record | Marketed in Canada as DACARBAZINE FOR INJECTION (DIN 02566702) under ATC L01AX04 DACARBAZINE. Indications are not published in the Drug… | DIN02566702 | approved | health-canada-dpd |
| — | Nadofaragene Firadenovec | Health Canada CA | cancer not stated in this record | Marketed in Canada as ADSTILADRIN (DIN 02566680) under ATC L01XL10 NADOFARAGENE FIRADENOVEC. Indications are not published in the Drug… | DIN02566680 | approved | health-canada-dpd |
| — | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB INJECTION (DIN 02566621) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug Product… | DIN02566621 | approved | health-canada-dpd |
| — | Bleomycin | Health Canada CA | cancer not stated in this record | Marketed in Canada as BLEOMYCIN FOR INJECTION (DIN 02566346) under ATC L01DC01 BLEOMYCIN. Indications are not published in the Drug Product… | DIN02566346 | approved | health-canada-dpd |
| — | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as NRA-BICALUTAMIDE (DIN 02565919) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02565919 | approved | health-canada-dpd |
| — | Rituximab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ADRUXE (DIN 02565781) under ATC L01FA01 RITUXIMAB. Indications are not published in the Drug Product Database — see… | DIN02565781 | approved | health-canada-dpd |
| — | Selpercatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as RETEVMO (DIN 02565668) under ATC L01EX22 SELPERCATINIB. Indications are not published in the Drug Product Database —… | DIN02565668 | approved | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE INJECTION (DIN 02565641) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product… | DIN02565641 | approved | health-canada-dpd |
| — | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as NRA-ANASTROZOLE (DIN 02565358) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02565358 | approved | health-canada-dpd |
| — | Nilotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-NILOTINIB (DIN 02565005) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database… | DIN02565005 | approved | health-canada-dpd |
| — | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AZACITIDINE FOR INJECTION (DIN 02564998) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug… | DIN02564998 | approved | health-canada-dpd |
| — | Nilotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-NILOTINIB (DIN 02564947) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database… | DIN02564947 | approved | health-canada-dpd |
| — | Zanidatamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZIIHERA (DIN 02564610) under ATC L01FD07 ZANIDATAMAB. Indications are not published in the Drug Product Database —… | DIN02564610 | approved | health-canada-dpd |
| — | Eribulin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ERIBULIN MESYLATE INJECTION (DIN 02564467) under ATC L01XX41 ERIBULIN. Indications are not published in the Drug… | DIN02564467 | approved | health-canada-dpd |
| — | Pegfilgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as DYRUPEG (DIN 02564394) under ATC L03AA13 PEGFILGRASTIM. Indications are not published in the Drug Product Database —… | DIN02564394 | approved | health-canada-dpd |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.